Immuron logo
Immuron
IMRN | NASDAQ
Chart Builder DCF Calculator
$0.90
+$0.02 (+2.82%)
At close: Nov 16, 2026, 4:00 PM ET
$0.92
+$0.02 (+1.72%)
After-hours: Nov 16, 2026, 7:00 PM ET

Immuron Company Profile

Company profile explained

Company Profile

Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.

Key Executives

Name Position
Steven George Lydeamore Chief Executive Officer
Aaron Laurita Chief Financial Officer
David Lyon Head of Marketing
Flavio Palumbo Chief Commercial Officer
Jerry Kanellos Chief Scientific Officer
Olga Smejkalova Company Secretary

Latest SEC Filings

Date Type Title
Oct 28, 2026 6-K Filing
Oct 27, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 23, 2026 424B5 Filing
Oct 22, 2026 6-K Filing
Oct 16, 2026 6-K Filing
Oct 13, 2026 6-K Filing
Sep 24, 2026 20-F Filing
Sep 24, 2026 6-K Filing
Sep 22, 2026 6-K Filing
View All SEC Filings ➞
Immuron
Immuron logo
Country Australia
IPO Date Jun 9, 2017
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Steven George Lydeamore

Contact Details

62 Lygon Street Carlton, VIC 3053 Australia

Stock Details

Ticker Symbol IMRN
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001660046
CUSIP Number 45254U101
ISIN Number US45254U1016
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.